Serono to Renege on Deal!!
Action Needed NOW!!
June 27, 1997
As you may recall, over a year ago members of the AIDS advocacy community negotiated a pricing agreement with Serono Laboratories, Inc. regarding the market price of the first and only FDA-approved drug Serostim (a human growth hormone) to treat "AIDS Wasting Syndrome."
Part of the deal included a "Treatment Continuation Program" for those patients requiring more than $36,000 worth of the product each year. Upon presenting pharmacy receipts documenting use of $36,000 worth of Serostim, Serono would continue to provide the drug to patients without charge for the remainder of that year. Unfortunately, right at the time when patients are beginning to incur this significant cost and finally have a chance to participate in the program, the company has decided to change the requirements for eligibility.
Now, instead of accepting a pharmacy print-out documenting that $36,000 worth of the drug had been distributed to the patient, Serono is requiring that a patient's insurance carrier must produce documentation that actual reimbursement has been made.
This creates a serious treatment problem for patients suffering from AIDS Wasting Syndrome because there is usually a two to three month lag-time from the date the prescription is filled and when one's insurance company makes reimbursement.
This article was provided by AIDS Action Council.